Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL399396 | 0.83 | NUDT1 (0.48) | NUDT1CDC7CDK2SRCMAPT | |
| Hydrochloric Acid SCHEMBL30404265 | 0.82 | NUDT1 (0.47) | NUDT1CDC7CDK2SRCMAPT | |
| SCHEMBL5493982 | 0.75 | MAPT (0.36) | SRCMAPTIDO1 | |
| SCHEMBL5316693 | 0.75 | SRC (0.34) | SRCMAPTIDO1 | |
| SCHEMBL12920665 | 0.75 | SRC (0.41) | SRCMAPTIDO1 | |
| SCHEMBL26121351 | 0.75 | SRC (0.34) | SRCMAPTIDO1 | |
| SCHEMBL30197390 | 0.72 | ADORA3 (0.39) | SRCMAPTIDO1LMNA | |
| SCHEMBL439909 | 0.71 | SRC (0.32) | SRCMAPTLMNA | |
| SCHEMBL21672753 | 0.71 | SRC (0.35) | SRC | |
| SCHEMBL31055794 | 0.71 | MAPT (0.38) | SRCMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199616-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-06-20 | — | — | US | disclosed |
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2018136265-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-7306631-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1732509-A1 | KERATIN DYEING COMPOSITIONS BICYCLIC 5-6 HETEROAROMATIC DYEING COMPOUNDS WITH ONE RING NITROGEN JUNCTION | The Procter and Gamble Company (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097052-A1 | KERATIN DYEING COMPOSITIONS BICYCLIC 5-6 HETEROAROMATIC DYEING COMPOUNDS WITH ONE RING NITROGEN JUNCTION | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050229333-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199616-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPN2 | NUDT1 3312/4885CDC7 2054/4885CDK2 818/4885 |
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN4 | NUDT1 4059/4885CDC7 1774/4885CDK2 733/4885 |
| US-20050229333-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, CKMT1A; CKMT1B, JUP | NUDT1 2262/4885CDC7 1817/4885CDK2 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.